Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the pricing of its underwritten offering (the "Offering") of…
News provided by PR Newswire.
